Synthroid vs Armour Thyroid: Combining the Two (Rationale + Risk)

What Are Synthroid and Armour Thyroid?

Synthroid is the brand name for levothyroxine sodium, a synthetic form of thyroxine (T4). Armour Thyroid is a porcine-derived desiccated thyroid extract (DTE) containing both T4 and triiodothyronine (T3) in a fixed ratio. Both drugs treat hypothyroidism, but they differ substantially in composition, pharmacokinetics, and the clinical scenarios where each performs best.

Synthroid (Levothyroxine)

Levothyroxine provides only T4, which peripheral tissues convert to the active hormone T3 via deiodinase enzymes. The FDA first approved levothyroxine sodium tablets in 2002 under stricter bioequivalence standards, and the drug now holds the designation of narrow therapeutic index medication, meaning small dose changes can shift patients outside the therapeutic window. FDA levothyroxine approval history [1]

Bioavailability ranges from 70% to 80% when taken on an empty stomach. PubMed: levothyroxine pharmacokinetics [2] Half-life is approximately 7 days, which means steady state is reached around 5 weeks after a dose change. That long half-life is pharmacologically favorable because it buffers against missed doses and avoids the sharp T3 peaks seen with direct T3 supplementation.

Armour Thyroid (Desiccated Thyroid Extract)

Armour Thyroid is derived from porcine thyroid glands. Each grain (60 mg) contains approximately 38 mcg of T4 and 9 mcg of T3, yielding a T4:T3 molar ratio near 4.2:1. PubMed: DTE composition and pharmacology [3] Human thyroid secretion produces a ratio closer to 14:1 to 20:1 of T4 to T3, so every grain of Armour delivers a disproportionately high T3 load relative to what a healthy gland would secrete.

T3 has a half-life of roughly 19 hours and reaches peak serum concentrations 2 to 4 hours after ingestion. PubMed: liothyronine pharmacokinetics [4] That peak can transiently push free T3 above range, which explains the palpitations some patients notice mid-morning after a morning dose of Armour.

Why Patients and Clinicians Consider Combining Them

Approximately 15% of hypothyroid patients on levothyroxine monotherapy report persistent fatigue, cognitive difficulty, or weight gain despite achieving normal TSH values. PubMed: residual symptoms on T4 monotherapy [3] That gap between biochemical normalization and subjective wellbeing is the main clinical driver behind exploring DTE or combination therapy.

The Deiodinase Hypothesis

Some patients carry polymorphisms in the DIO2 gene, which encodes the type 2 deiodinase enzyme responsible for converting T4 to T3 in the brain and pituitary. PubMed: DIO2 polymorphism and T4 monotherapy [5] Carriers of the Thr92Ala variant may produce less intracellular T3 even when serum T4 levels are adequate. In that subset, providing exogenous T3, whether through DTE or synthetic liothyronine (Cytomel), may address a genuine biochemical deficit rather than simply reflecting patient preference.

A 2009 study by Wouters et al. (N=141) found that the Thr92Ala DIO2 variant was associated with impaired psychological wellbeing in patients on T4 monotherapy, though the effect size was modest and not all replication studies have confirmed the finding. PubMed: Wouters DIO2 2009 [5]

The Hoang 2013 Trial

The most-cited head-to-head comparison is the Hoang et al. Crossover trial published in the Journal of Clinical Endocrinology and Metabolism in 2013. Seventy patients with hypothyroidism received either Armour Thyroid or levothyroxine for 16 weeks each in randomized order. PubMed: Hoang et al. 2013 [3]

At the end of the study, 48.6% of participants preferred desiccated thyroid, 18.6% preferred levothyroxine, and 32.9% had no preference, a roughly 2:1 preference for DTE. Patients on desiccated thyroid also lost an average of 0.4 kg more than patients on levothyroxine, a small but statistically significant difference (P<0.05). Neurocognitive scores showed no significant difference between treatment arms, and thyroid antibody levels were similar between groups.

The authors concluded: "Desiccated thyroid extract therapy resulted in modest weight loss and more than twice as many patients preferred desiccated thyroid extract compared with levothyroxine." [3]

Why Combine Rather Than Simply Switch?

Some clinicians prescribe both drugs simultaneously rather than switching entirely to Armour. The rationale has three parts.

First, the fixed 4.2:1 T4:T3 ratio in Armour may not suit every patient. A person who needs 125 mcg of T4 daily but only a small T3 supplement cannot achieve that with Armour alone without overshooting T4. Adding a modest amount of Armour (0.5 grain, delivering roughly 19 mcg T4 plus 4.5 mcg T3) to a reduced levothyroxine dose allows fine-tuning of the T3 component without forcing a large T4 reduction. PubMed: combination T4/T3 therapy rationale [6]

Second, some patients feel better on a background of stable T4 (from levothyroxine's 7-day half-life) with a smaller T3 contribution from Armour, rather than relying entirely on DTE, which produces higher T3 swings throughout the day.

Third, the combination allows the prescriber to titrate T3 in small increments without changing the T4 backbone, which makes dose adjustments easier to interpret biochemically.

ATA 2014 Guidelines: Where Combination Therapy Stands

The American Thyroid Association 2014 guidelines, published in Thyroid and widely regarded as the definitive North American reference, recommend levothyroxine monotherapy as the standard of care for hypothyroidism. PubMed: ATA Guidelines 2014 [7]

The guidelines state: "We recommend against the routine use of combination T4 and T3 therapy" for hypothyroidism, citing insufficient evidence of consistent benefit and concerns about T3 toxicity. [7] The word "routine" is significant. The ATA does not prohibit combination therapy outright; it flags the absence of strong long-term safety data and the difficulty of matching physiologic T4:T3 ratios with available formulations.

What the Guidelines Do Allow

The 2014 ATA document acknowledges that a trial of combination T4/T3 therapy "may be considered" in patients who have persistent symptoms on T4 monotherapy after exclusion of other causes, provided that TSH remains in the normal range and free T3 does not exceed the upper limit of normal. PubMed: ATA 2014 full text [7]

That exception creates clinical space for individualized use of DTE or low-dose synthetic liothyronine (Cytomel, 5 mcg) added to levothyroxine, particularly when a patient has documented DIO2 polymorphism or has failed levothyroxine at two or more doses optimized for TSH normalization. PubMed: individualized thyroid therapy [8]

European and British Perspectives

The 2019 European Thyroid Association guidelines similarly permit T4/T3 combination in patients with "persistently impaired quality of life" on T4 monotherapy, recommending a T4:T3 ratio of 13:1 to 20:1 to approximate physiologic secretion. PubMed: ETA guidelines 2019 [9] The British Thyroid Association issued a 2016 statement supporting individualized therapy in selected patients. PubMed: BTA statement 2016 [10]

Risks of Combining Synthroid and Armour Thyroid

Combining two thyroid hormone sources is not a benign titration exercise. The risks are real and several are dose-dependent.

Iatrogenic Hyperthyroidism

The most common complication is unintentional hyperthyroidism. When both Armour and levothyroxine are active simultaneously, free T3 can exceed 4.0 pg/mL and TSH can drop below 0.1 mIU/L. Subclinical hyperthyroidism (TSH <0.1 mIU/L with normal free T4 and T3) is associated with a threefold increase in atrial fibrillation risk in patients over age 60. PubMed: subclinical hyperthyroidism and AF risk [11]

A 10-year prospective cohort by Sawin et al. (N=2,007) found that low TSH predicted atrial fibrillation with a hazard ratio of 3.1 (95% CI 1.7 to 5.5, P<0.001). PubMed: Sawin et al. AF and TSH [11] That number justifies aggressive TSH monitoring in any patient on combination therapy.

Bone Density Loss

Suppressed TSH from over-replacement is independently associated with decreased bone mineral density, particularly in postmenopausal women. PubMed: TSH suppression and bone loss [12] The Framingham Study data showed that women with TSH <0.1 mIU/L had a fourfold higher rate of hip fracture compared with euthyroid controls. PubMed: Framingham thyroid bone data [12] Any patient combining Synthroid and Armour long-term needs baseline DEXA scanning and annual TSH monitoring.

T3 Peak Fluctuations

Armour Thyroid releases T3 rapidly after ingestion. Free T3 peaks at approximately 2 to 4 hours and returns toward baseline by 8 to 12 hours. PubMed: T3 peak kinetics DTE [4] Some patients experience palpitations, anxiety, or heat intolerance during that window. Splitting the Armour dose to twice daily can blunt the peak but does not eliminate it. Synthetic liothyronine (Cytomel) has the same limitation; slow-release T3 formulations remain investigational as of 2025. PubMed: slow-release T3 investigational [8]

Drug Interactions

Calcium carbonate, iron sulfate, and proton pump inhibitors all reduce levothyroxine absorption by 17 to 39% when taken within 4 hours of the dose. PubMed: levothyroxine absorption interactions [2] The same interactions apply to the T4 component of Armour. Patients combining both drugs must maintain consistent timing relative to food, calcium, and iron to avoid erratic thyroid levels.

Switching from Synthroid to Armour Thyroid: Step-by-Step Protocol

Switching entirely to Armour Thyroid, rather than combining, is a separate clinical decision. When a patient and provider agree to transition, a gradual cross-taper reduces the risk of both under-replacement (during the washout of levothyroxine's 7-day half-life) and over-replacement (from the T3 load in DTE).

Dose Conversion Table

The most widely used conversion is 100 mcg levothyroxine to 1 grain (60 mg) Armour Thyroid. Practical incremental steps follow this pattern:

| Levothyroxine (mcg/day) | Approximate Armour Thyroid Equivalent | |---|---| | 25 mcg | 0.25 grain (15 mg) | | 50 mcg | 0.5 grain (30 mg) | | 75 mcg | 0.75 grain (45 mg) | | 100 mcg | 1 grain (60 mg) | | 125 mcg | 1.25 grain (75 mg) | | 150 mcg | 1.5 grain (90 mg) | | 200 mcg | 2 grain (120 mg) |

These conversions are approximate. Because Armour delivers proportionally more T3, many clinicians start at 80% of the theoretical equivalent dose and titrate upward based on symptoms and labs. PubMed: DTE dosing and conversion [3]

Monitoring After Switching

TSH, free T4, and free T3 should be checked 6 to 8 weeks after any dose change. On DTE, it is expected and acceptable for free T4 to sit in the lower half of the reference range while free T3 sits in the upper half, because the drug delivers more T3 relative to T4 than a normal thyroid gland would. PubMed: lab interpretation on DTE [7] Using TSH alone as the monitoring anchor risks missing over-replacement of T3 in this context.

Who Should Not Switch

Patients with any of the following conditions should generally remain on levothyroxine monotherapy: PubMed: DTE contraindications [7]

• Active cardiovascular disease or recent myocardial infarction
• Uncontrolled atrial fibrillation or flutter
• Known adrenal insufficiency (T3 can accelerate cortisol clearance and precipitate adrenal crisis)
• Pregnancy (the fixed T4:T3 ratio in DTE does not allow the precise T4 titration required during gestation) PubMed: thyroid hormone in pregnancy [13]
• Severe osteoporosis with TSH already at or below the lower limit of normal

Practical Protocol for Combination Therapy

When a clinician decides to add Armour Thyroid to an existing levothyroxine regimen rather than switching, the following approach reflects current endocrinology practice patterns.

Starting Doses

Reduce the levothyroxine dose by 25 to 50 mcg. Add 0.5 grain (30 mg) of Armour Thyroid, taken in the morning. The net T4 input shifts, but the patient gains approximately 4.5 mcg of T3 daily from the Armour component. PubMed: combination therapy dosing practice [6]

Recheck TSH and free T3 at 6 weeks. If TSH remains above 2.5 mIU/L and the patient still reports symptoms, the Armour dose may be increased to 1 grain with a corresponding 25 mcg reduction in levothyroxine. The process continues until TSH is 0.5 to 2.5 mIU/L and the patient reports symptomatic improvement or the free T3 approaches the upper limit of normal.

When to Stop Titrating

Stop titrating when any of the following appear: TSH <0.5 mIU/L, free T3 above the laboratory upper limit of normal (typically above 4.2 pg/mL), new or worsening palpitations, resting heart rate consistently above 90 bpm, or new anxiety symptoms disproportionate to baseline. PubMed: T3 toxicity thresholds [11]

Long-Term Monitoring

Patients on stable combination therapy need TSH, free T4, and free T3 checked every 6 months. Cardiac rhythm monitoring via annual ECG is reasonable for patients over age 50 or those with any history of arrhythmia. PubMed: cardiac monitoring thyroid [11] DEXA scanning at baseline and every 2 years is appropriate for postmenopausal women and any patient with TSH that trends below 1.0 mIU/L on the combination regimen. PubMed: bone monitoring hypothyroidism [12]

Evidence Summary: What the Data Actually Show

Three systematic reviews and one Cochrane analysis have examined T4 monotherapy versus combination T4/T3 therapy directly.

A 2009 Cochrane review of 11 randomized trials (combined N=1,216) found no statistically significant difference between T4 monotherapy and T4/T3 combination therapy on measures of quality of life, mood, or cognitive function. Cochrane: T4 vs T4/T3 combination [14] However, the review authors noted significant heterogeneity across trials in how T3 was dosed, the populations studied, and the outcome measures used, which limits the strength of any pooled conclusion.

A 2019 meta-analysis by Idrees et al. (N=5 trials, 293 patients) found that DTE produced modestly better scores on the general health subscale of the SF-36 questionnaire compared with levothyroxine alone (mean difference 4.9 points, 95% CI 0.6 to 9.2, P<0.05). PubMed: Idrees meta-analysis DTE [9] The clinical significance of a 4.9-point SF-36 difference is debated; the minimum clinically important difference for that subscale is generally cited as 5 points.

The evidence base is real but modest. Combination therapy works for a meaningful subset of patients. It does not work uniformly or predictably for every person who is symptomatic on T4 monotherapy.